RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 554,532 shares, a drop of 53.0% from the June 15th total of 1,180,532 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
RemeGen Price Performance
Shares of RemeGen stock opened at $9.50 on Wednesday. The company has a 50 day moving average of $10.59 and a 200-day moving average of $10.42. RemeGen has a 1-year low of $9.50 and a 1-year high of $15.91.
RemeGen Company Profile
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
See Also
- Five stocks we like better than RemeGen
- Marriott vs. Viking: Why the Better Quarter Doesn’t Mean the Better Decade
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
